News
Regulus Therapeutics (RLS) contingent value right may be worth $3-$4 a share in its planned sale to Novartis (NVS), according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback